The Food and Drug Administration allows faster drug approvals based on preliminary study data if the drug fulfills an unmet medical need. But the speedy approval comes with a promise that the drugmaker does another clinical trial once the drug is on the market to prove it really works. If not, the FDA can rescind the approval. How are the companies doing and how well does the agency enforce that system? Pharmaceuticals correspondent Sydney Lupkin investigated the 30-year track record for accelerated approvals. Today, her findings on stalled trials and missing evidence.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Short Wave
Transcribed and ready to explore now
Parasites Have Haunted Us For Millions Of Years
24 Oct 2025
Short Wave
Migrating Birds Have a Big, Clear Problem
22 Oct 2025
Short Wave
We Have the Cure. Why is Tuberculosis Still Around?
21 Oct 2025
Short Wave
Should Scientists Genetically Engineer Wild Species?
20 Oct 2025
Short Wave
Science Says Quitting Smoking At Any Age Is Good For The Brain
17 Oct 2025
Short Wave
What Happens When You're Under Anesthesia?
15 Oct 2025
Short Wave